# Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

> **NCT02800889** · PHASE1 · WITHDRAWN · sponsor: **CTI BioPharma**

## Conditions studied

- Lymphoma
- Solid Tumor (Excluding CNS)

## Interventions

- **DRUG:** Pixantrone

## Key facts

- **NCT ID:** NCT02800889
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-10-24
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-07-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn; no participants enrolled
- **Last updated:** 2020-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02800889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02800889, "Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02800889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*